Chest, Vol 101, 350-355, Copyright © 1992 by American College of Chest Physicians

ARTICLES

Failure of inhaled corticosteroids to modify bronchoconstrictor or bronchodilator responsiveness in middle-aged smokers with mild airflow obstruction

A Watson, TK Lim, H Joyce and NB Pride
Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, England.

We have compared the effects of three-month periods of treatment with an inhaled corticosteroid, budesonide 600 micrograms twice daily and with placebo on bronchial responses to inhaled histamine and to bronchodilators in a double-blind crossover trial in 14 middle-aged male smokers (mean age, 59.6 years) with mild airways obstruction (mean FEV1 2.42 L, 80 percent predicted [range, 48 to 110 percent]). Responsiveness to inhaled histamine was assessed monthly by the provocative concentration (mg/ml) reducing FEV1 by 20 percent (PC20). Bronchodilator response to a combination of inhaled salbutamol (5 mg) and ipratropium (0.5 mg) was assessed before and after three months' treatment. Compliance with treatment was checked by weighing aerosol canisters, and by measuring plasma budesonide and metabolites. There was no significant change in FEV1 (budesonide mean 2.38 L [SEM 0.17] vs placebo 2.40 L [0.17]), vital capacity (budesonide mean 3.69 L [0.17] vs placebo 3.81 L [0.17]) or in bronchodilator responsiveness (mean increase over baseline FEV1, budesonide 11.6 [2.7] percent vs placebo 10.5 [3.2] percent). There was a small overall reduction in bronchoconstrictor responsiveness over the period of the trial, but there was no effect of 12 weeks of budesonide treatment compared with 12 weeks of placebo treatment (mean log PC20 during budesonide 0.595 [SEM 0.063], placebo 0.591 [SEM 0.055]). Following the three-month crossover trial, six men continued for nine more months to receive budesonide in a single-blind trial and the results were compared with those in six men who took no active treatment for the subsequent nine months. No improvements in baseline spirometry, home peak flow measurements, bronchoconstrictor or bronchodilator responsiveness were observed after 12 months of budesonide treatment. Thus, a regimen of budesonide treatment that consistently attenuates bronchial responsiveness in asthmatic subjects had no effect in these men; larger and longer trials will be required to establish whether a subgroup of smokers shows a favorable response.

This article has been cited by other articles:

				J. F. Donohue and J. A. Ohar Effects of Corticosteroids on Lung Function in Asthma and Chronic Obstructive Pulmonary Disease Proceedings of the ATS, November 1, 2004; 1(3): 152 - 160. [Abstract] [Full Text] [PDF]

				G T Verhoeven, J P J J Hegmans, P G H Mulder, J M Bogaard, H C Hoogsteden, and J-B Prins Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness Thorax, August 1, 2002; 57(8): 694 - 700. [Abstract] [Full Text] [PDF]

				W. R. Douma, H. A. M. Kerstjens, A. de Gooijer, S. E. Overbeek, G. H. Koeter, and D. S. Postma Initial Improvements in Lung Function and Bronchial Hyperresponsiveness Are Maintained During 5 Years of Treatment With Inhaled Beclomethasone Dipropionate and Terbutaline Chest, January 1, 2002; 121(1): 151 - 157. [Abstract] [Full Text] [PDF]

				B. Balbi, M. Majori, S. Bertacco, G. Convertino, A. Cuomo, C. F. Donner, and A. Pesci Inhaled Corticosteroids in Stable COPD Patients : Do They Have Effects on Cells and Molecular Mediators of Airway Inflammation? Chest, June 1, 2000; 117(6): 1633 - 1637. [Abstract] [Full Text] [PDF]

				P. J. BARNES Inhaled Corticosteroids Are Not Beneficial in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., February 1, 2000; 161(2): 342 - 344. [Full Text]

				S. V. CULPITT, W. MAZIAK, S. LOUKIDIS, J. A. NIGHTINGALE, J. L. MATTHEWS, and P. J. BARNES Effect of High Dose Inhaled Steroid on Cells, Cytokines, and Proteases in Induced Sputum in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., November 1, 1999; 160(5): 1635 - 1639. [Abstract] [Full Text]

				D. S. POSTMA and H. A. M. KERSTJENS Are Inhaled Glucocorticosteroids Effective in Chronic Obstructive Pulmonary Disease? Am. J. Respir. Crit. Care Med., November 1, 1999; 160(5): S66 - 71. [Abstract] [Full Text] [PDF]

				R. A. Pauwels, C.-G. Lofdahl, L. A. Laitinen, J. P. Schouten, D. S. Postma, N. B. Pride, S. V. Ohlsson, and The European Respiratory Society Study on Chronic Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease Who Continue Smoking N. Engl. J. Med., June 24, 1999; 340(25): 1948 - 1953. [Abstract] [Full Text] [PDF]

				G. Cox, L. Whitehead, M. Dolovich, M. Jordana, J. Gauldie, and M. T. Newhouse A Randomized Controlled Trial on the Effect of Inhaled Corticosteroids on Airways Inflammation in Adult Cigarette Smokers Chest, May 1, 1999; 115(5): 1271 - 1277. [Abstract] [Full Text] [PDF]

				P M van Grunsven, C P van Schayck, J P Derenne, H A M Kerstjens, T E J Renkema, D S Postma, T Similowski, R P Akkermans, P C M P.-d. Jong, P N R Dekhuijzen, et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis Thorax, January 1, 1999; 54(1): 7 - 14. [Abstract] [Full Text]

				P. J. BARNES, S. PEDERSEN, and W. W. BUSSE Efficacy and Safety of Inhaled Corticosteroids . New Developments Am. J. Respir. Crit. Care Med., March 1, 1998; 157(3): S1 - 53. [Full Text] [PDF]

				J. E. REPINE, A. BAST, I. LANKHORST, and The Oxidative Stress Study Gro Oxidative Stress in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., July 1, 1997; 156(2): 341 - 357. [Full Text]

				P. J. Barnes Inhaled Glucocorticoids for Asthma N. Engl. J. Med., March 30, 1995; 332(13): 868 - 875. [Full Text] [PDF]

				S. E. Weinberger Recent Advances in Pulmonary Medicine- First of Two Parts N. Engl. J. Med., May 13, 1993; 328(19): 1389 - 1397. [Full Text]